JNJ Mar 2025 180.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

35.22

0.00

(0.00%)

At close: 11:19AM EDT

Loading interactive chart…

Zacks
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
J&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
Zacks
The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly
Pfizer, Johnson & Johnson and Eli Lilly are part of the Zacks top Analyst Blog.
Business Wire
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
NEW BRUNSWICK, N.J., June 21, 2024--Johnson & Johnson (NYSE: JNJ) announced today that it has successfully completed the acquisition of Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash with potential for an additional milestone payment, as announced on May 16, 2024.